Provided by Tiger Fintech (Singapore) Pte. Ltd.

United Therapeutics

325.82
+6.111.91%
Post-market: 329.984.16+1.28%17:18 EDT
Volume:317.04K
Turnover:103.04M
Market Cap:14.70B
PE:12.98
High:326.30
Open:322.99
Low:322.60
Close:319.71
Loading ...

CFO and Treasurer James Edgemond Reports Disposal of Common Shares in United Therapeutics Corporation

Reuters
·
04 Jun

United Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
02 Jun

Cantor Fitzgerald Initiates United Therapeutics at Overweight With $405 Price Target

MT Newswires Live
·
02 Jun

Court Denies United Therapeutics' Injunction Request, Paving the Way for Liquidia's YUTREPIA Launch

Reuters
·
02 Jun

Hold Rating for United Therapeutics Amid Competitive Pressures from LQDA’s Yutrepia

TIPRANKS
·
28 May

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

StockStory
·
27 May

Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension

MT Newswires Live
·
24 May

FDA Approves Liquidia's YUTREPIA for Pulmonary Hypertension, Paving Way for Commercial Launch

Reuters
·
24 May

U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

GlobeNewswire
·
24 May

Paul A. Mahon, EVP & General Counsel, Reports Disposal of United Therapeutics Corporation Common Shares

Reuters
·
21 May

Director Tommy G. Thompson Reports Disposal of Common Shares of United Therapeutics Corporation

Reuters
·
13 May

Liquidia Faces Patent Litigation Filed by United Therapeutics

MT Newswires Live
·
12 May

United Therapeutics Price Target Maintained With a $425.00/Share by HC Wainwright & Co.

Dow Jones
·
05 May

Court dismisses United Therapeutics’ dispute against Liquidia

TIPRANKS
·
03 May

Liquidia rallies after judge rules against bid to delay Yutrepia

TIPRANKS
·
03 May

United Therapeutics First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.
·
02 May

United Therapeutics Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
02 May

UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales

Zacks
·
01 May

U.S. RESEARCH ROUNDUP-Avepoint, Meta, United Therapeutics

Reuters
·
01 May

Q1 2025 United Therapeutics Corp Earnings Call

Thomson Reuters StreetEvents
·
01 May